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ABSTRACT
Objective To determine whether steroids plus antivirals
provide a better degree of facial muscle recovery in
patients with Bell’s palsy than steroids alone.
Design Meta-analysis.
Data sources PubMed, Embase, Web of Science, and the
Cochrane Central Register of Controlled Trials were
searched for studies published in all languages from
1984 to January 2009. Additional studies were identified
from cited references.
Selection criteria Randomised controlled trials that
compared steroids with the combination of steroids and
antiviralsforthetreatmentofBell’spalsywereincludedin
this study. At least one month of follow-up and a primary
end point of at least partial facial muscle recovery, as
defined by a House-Brackmann grade of at least 2
(complete palsy is designated a grade of 6) or an
equivalent score on an alternative recognised scoring
system, were required.
Review methods Two authors independently reviewed
studies for methodological quality, treatment regimens,
duration of symptoms before treatment, length of follow-
up, and outcomes. Odds ratios with 95% confidence
intervals were calculated and pooled using a random
effects model.
Results Six trials were included, a total of 1145 patients;
574 patients received steroids alone and 571 patients
received steroids and antivirals. The pooled odds ratio for
facial muscle recovery showed no benefit of steroids plus
antivirals compared with steroids alone (odds ratio 1.50,
95%confidenceinterval0.83to2.69;P=0.18).Aonestudy
removed analysis showed that the highest quality studies
had the greatest effect on the lack of difference between
study arms shown by the odds ratio. Subgroup analyses
assessing causes of heterogeneity defined a priori (time
fromsymptomonsettotreatment,lengthoffollow-up,and
typeofantiviralstudied)showednobenefitofantivirals in
addition to that provided by steroids.
ConclusionsAntiviralsdidnotprovideanaddedbenefitin
achievingatleastpartialfacialmusclerecoverycompared
withsteroidsaloneinpatientswithBell’spalsy.Thisstudy
does not, therefore, support the routine use of antivirals
in Bell’s palsy. Future studies should use improved
herpes virus diagnostics and newer antivirals to assess
whethercombinationtherapybenefitspatientswithmore
severe facial paralysis at study entry.
INTRODUCTION
Bell’s palsy is the abrupt paralysis of the facial nerve,
resultinginaninabilitytocontrolfacialmusclesonthe
affectedside.Acommoncondition,Bell’spalsyhasan
annual incidence of 11 to 40 cases per 100000
population.
1 Many patients recover without inter-
vention; however, up to 30% have poor recovery of
facial muscle control and experience facial disfigure-
ment, psychological trauma, and facial pain.
2 Two
main types of pharmacological treatment have been
used to improve outcomes from Bell’s palsy: steroids
and antivirals.
3 The rationale for these treatments is
based on the presumed pathophysiology of Bell’s
palsy, namely inflammation and viral infection.
For decades, surgeons have noted facial nerve swel-
ling during decompression surgery.
4 More recently,
enhancement of the facial nerve on magnetic resonance
imaging has been observed in Bell’s palsy, suggesting
thatinflammationisinpartresponsiblefortheassociated
paralysis.
5As a consequence, steroids have beenusedto
treat Bell’s palsy and have been shown to significantly
improve outcomes compared with placebo.
6
The neuronal inflammation associated with Bell’s
palsy is thought to be secondary to viral infection.
Herpes simplex virus has been detected in the endo-
neurial fluid in patients with Bell’s palsy.
7 On the basis
of this evidence, some clinicians treat patients with
antivirals, including aciclovir, famciclovir, and
valaciclovir.
8 The benefits of antivirals alone are not
clear, thus the role of combination therapy with ster-
oids plus antivirals has been investigated for the treat-
ment of Bell’s palsy.
69-17 Studies have produced
somewhat conflicting results, however, and there is
debate over the effectiveness of antivirals on top of
steroids.
18 The most recent guidelines from the Amer-
ican Academy of Neurology suggest that aciclovir
combined with prednisone is “possibly effective” for
Bell’s palsy.
19 Despite a lack of clear evidence, many
clinicians treat Bell’s palsy with combination therapy.
Given the emergence of this clinical practice and the
conflicting data on the benefits of antivirals over and
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to determine whether steroid treatment plus antivirals
providesabetterdegreeoffacialmusclerecoverythan
does steroids alone.
METHODS
Search strategy and selection criteria
This review was conducted to the suggested
QUOROM guideline standards.
20 We began our
meta-analysis by performing a detailed literature
search for articles published between 1984 (year that
aciclovir was licensed for clinical use) and January
2009 using PubMed, Embase, Web of Science, and
the Cochrane Central Register of Controlled Trials.
In addition, we searched reference lists of systematic
reviews for appropriate articles. Hand searching of
conference abstract books was not performed. Our
search terms included: “bell palsy,”“ bell’s palsy,”
“bell’s palsies,”“ bells palsy,”“ idiopathic facial para-
lyses,”“ idiopathic facial paralysis,”“ herpetic facial
paralysis,”“ anti-viral agents,”“ acyclovir,”“ valacyclo-
vir,”“ famcyclovir,” and “famciclovir.” Steroids were
not included in the search terms as we were not inter-
ested in studies that only assessed the benefits of ster-
oids alone. Two independent investigators performed
the search.
We included all randomised controlled trials that
compared steroids with the combination of steroids
and antivirals in patients with Bell’s palsy. No studies
were excluded on the basis of language. Other inclu-
sion criteria included: at least one month of follow-up
after treatment initiation; and an assessment of facial
muscle recovery, as determined by a recognised scor-
ingsystemsuchastheHouse-Brackmanngrade,Yana-
gihara score, or the facial paralysis recovery index.
21
We excluded animal studies, review articles, meta-
analyses, case series, studies involving children or
pregnant women, studies lacking a control group, stu-
dies that did not report the proportion of patients with
facial recovery, and studies comparing steroids with
antivirals alone. Where duplicate papers using over-
lapping data sets were published, the study with the
larger population was included.
Data extraction and quality assessment
The following variables were extracted from all stu-
dies: (a) year of publication; (b) geographic region of
the study; (c) study design; (d) patient demographics;
(e) number of patients in each treatment group;
(f) type of antiviral used and dose; (g) type of steroid
used and dose; (h) duration of symptoms before treat-
ment initiation, (i) length of follow-up; (j) type of facial
muscle recovery outcome scale used; (k) definition for
facial recovery; and (l) proportion of patients with
facialrecoveryateachfollow-uptimepoint.Twoinde-
pendent reviewers extracted the data from each study.
There was one inter-reviewer disagreement during
dataextraction,whichwasresolvedbyathirdindepen-
dent reviewer. The Sullivan et al,
6 the Minnerop et al,
9
and the Adour et al
22 studies did not report the
necessary data regarding the groups of interest; the
correspondingauthorswerecontactedandkindlypro-
vided the necessary information.
Two independent investigators evaluated study
quality. Given that all included studies were rando-
mised controlled trials, the Jadad score was used to
assess study quality.
23 This scoring system evaluates
the randomisation process (two questions), blinding
(two questions), and the description of withdrawals
and dropouts (one question). The included studies
were then ranked from one to six, with one being the
highest quality study. Studies with the same Jadad
score were differentiated by the number of patients in
the study, with the study containing a larger sample
size receiving a higher rank.
Primary outcome
The primary outcome of this meta-analysis was the
proportionofpatientswithatleastpartialfacialmuscle
recovery from Bell’s palsy at the longest follow-up
point and who attended a follow-up visit at least one
month after initiation of treatment. Partial facial mus-
clerecoverywasdefinedasaHouse-Brackmanngrade
of at least 2 or an equivalent score on an alternative
scoring system.
21 Complete facial muscle recovery
wasdefinedasaHouse-Brackmanngradeof1.Despite
their importance to this disease, secondary outcome
measures such as facial pain or disfigurement were
not consistently reported by investigators and were
thus not analysed in this meta-analysis.
Statistical analysis
The Comprehensive Meta-Analysis software (CMA
version 2; Biostat, Englewood, NJ) was used for all sta-
tistical analyses. We calculated a pooled odds ratio and
95% confidence interval for the proportion of patients
withatleastpartialfacialmusclerecoverywhoweretrea-
ted with steroids plus antivirals compared with those
who received steroids alone. An odds ratio of greater
than one favours steroids plus antivirals, and the odds
ratio would be considered statistically significant at the
P<0.05 level if the 95% confidence interval does not
include the value 1. Despite communication with
Adour et al, we were unable to determine which inter-
vention arm three of the 20 patients lost to follow-up
were randomised to.
22 Therefore, patients lost to
follow-up were excluded in order to ensure consistent
analyses were performed across all studies. We also
usedintentiontotreatdataforallstudiesexceptAdouret
al
22; for this study, we performed a sensitivity analysis
under the extreme assumption that the three patients
lost to follow-up had been randomised to the steroid
arm or the steroid plus antiviral arm.
Givenourexpectationofheterogeneitybetweenstu-
dies,we useda randomeffectsmodeltoassessthe data
and performed a standard quantitative test of hetero-
geneity: the I
2 statistic, which describes the percentage
of total variation across studies that is attributable to
heterogeneity rather than chance alone. We also eval-
uated publication bias using a funnel plot
24 and a trim
and fill analysis,
25 which is an algorithm that assesses
the symmetry of a funnel plot via rank correlation and
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odds ratio and 95% confidence interval were recalcu-
lated after the addition of potential missing studies.
Sources of possible heterogeneity between studies
were determined a priori and were evaluated in our
analysis. These included: study quality; time between
symptom onset and treatment; length of follow-up;
and type of antiviral studied. Type of scoring system
usedforfacialmusclerecoverywasnotthoughttobea
source of heterogeneity, as the three systems used in
the included studies are comparable.
21 We performed
an analysis using a cumulative random effects model
based on the definedsourcesof heterogeneity, starting
with the highest quality study and continuing in
decreasing order, and a one study removed model to
determinetherelativecontributionofeachstudytothe
overall random effects estimate. Furthermore, sub-
group analyses were performed for time from symp-
tom onset to treatment (divided into ≤3 days and
>3 days), length of follow-up (≤3 months and
>3months),andtypeofantiviral.Interactionsbetween
subgroups were also assessed using an analysis of var-
iance (F test).
RESULTS
Studies included
The results of our search strategy are shown in fig 1. A
total of 521 studies were extracted from the search.
Fourteen studies met our inclusion criteria and under-
went thorough review. Of these, eight were removed
for the following reasons: they were not a randomised
study(n=3)
131617; theproportionofpatientswithfacial
musclerecoverywasnotdocumented(n=3)
111526;they
comprised a conference abstract only (n=1)
27; or they
studied a poorly defined intervention (n=1).
28 Of the
six remainingstudies,four were doubleblind, onewas
a single blind, and one was a non-blinded randomised
controlled trial.
The study demographics and clinical characteristics
of the six included studies are shown in tables 1 and 2,
respectively. A total of 574 patients who received ster-
oids alone and 571 patients who received steroids and
antivirals were included. Three studies used aciclovir
as the antiviral,
61022two studies used valaciclovir,
1214
and one study used famciclovir.
9 Most of the included
studieswere ofhighquality(Jadadscore≥3)exceptfor
Minneropetal,
9whichwasnotblinded.Studiesvaried
with respect to the duration of symptoms before treat-
ment initiation and length of follow-up. Two studies
subdivided patients into those who presented early
for treatment (≤3 days of symptom onset)
610121422
and those who presented later (>3 days).
1012 Length
of follow-up varied between studies and ranged from
4monthstomorethan12months;sometrialshadmul-
tiple follow-up times.
Outcomes for meta-analysis
The proportion of patients with at least partial facial
muscle recovery at the longest follow-up time in both
the steroids only group and the steroids plus antivirals
group is shown in fig 2. A high proportion of patients
with Bell’s palsy achieved at least partial facial recov-
ery when given steroids or steroids and antivirals
(89.7% overall using per protocol data). The pooled
proportion of patients with facial muscle recovery
was 88.2% (506/574) among those who received ster-
oids alone compared with 91.2% (521/571) in those
who received steroids and antivirals. The odds ratio
favoured combination therapy in four studies,
9101222
but the confidence intervals crossed 1 in three of
these (fig 2). The two highest quality studies had odds
ratiosthatwerelessthanone,favouringsteroidsalone,
with confidence intervals also crossing 1.
614
After performing an analysis using a random effects
model that included all six studies, the degree of facial
musclerecoverywasnotsignificantlybetterinpatients
who received steroids plus antivirals than in patients
whoreceivedsteroidsalone(oddsratio1.50, 95%con-
fidence interval 0.83 to 2.69; P=0.18). The I
2 statistic
for this model was 47.1%, suggesting heterogeneity
between studies. No significant difference in results
was observed when a fixed effects model was used or
whenintentiontotreatdatafromeachstudywereused
(data not shown). This held true whether the three
unaccounted lost to follow-up patients from the
Adour et al study
22 were added to the steroid arm
(1.30, 0.99 to 1.71; P=0.063) or the steroid plus anti-
viral arm (1.25, 0.98 to 1.60; P=0.072).
Toassesstheeffectofstudyqualityonourresults,we
performed a cumulative forest plot analysis based on
quality rank (highest to lowest; fig 3 ). This revealed
that the lower quality studies were responsible for
drawing the pooled odds ratio towards favouring ster-
oids plus antivirals. Despite this relationship, the con-
fidence interval for each cumulative odds ratio always
crossed 1. In addition, we performed a one study
removed analysis to assess the influence of any one
PubMed, Embase, Web of Science, and Cochrane Central Register of Controlled Trials (n=521)
PubMed (n=118), Embase (n=251), Web of Science (n=94), Cochrane (n=58)
All treatment trials comparing steroids with steroids plus antivirals (n=14)
Studies analysed (n=6)
References excluded (n=507)
  No original data (reviews)
  No comparison group
  Compared steroids to antivirals only
  Duplicate study
  Included children
  Included pregnant women              
  Animal study
References read in detail excluded (n=8)
  Ramos Macia et al 1992
26: analysed time to recovery
  Antunes et al 2000
15: analysed time to recovery
  Anpalahan and Redhead 2000
16: not randomised
  Furuta et al 2001
28: descriptive, no intervention
  Hato et al 2003
13: not randomised
  Roy et al 2005
27: conference abstract, no paper
  Ahangar et al 2006
17: not randomised
  Kawaguchi et al 2007
11: used hazard ratios
Fig 1 | Flow diagram of the study selection process. The initial study numbers from each
database do not represent the number of unique articles. Duplicate articles from different
databases were removed in the first exclusion stage
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This showed that the random effects estimate was not
greatly influenced by any one particular study except
for the two highest quality studies, Sullivan et al
6 and
Engstrom et al.
14 As expected, a more pronounced
effectofsteroidsplusantiviralscomparedwithsteroids
alone was observed after either of these studies was
removed.
A funnel plot suggested publication bias (fig 5).
Whenstudiescalculatedusingatrimandfillalgorithm
wereadded,
25theeffectofsteroidsplusantiviralscom-
pared with steroids alone was even less.
Subgroup analyses
Weperformedsubgroupanalysesrelatedtothesources
of heterogeneity we determined a priori. We observed
nobenefitofaddingantiviralstosteroidsinpatientswho
received treatment within three days (odds ratio 1.51,
95% confidence interval 0.68 to 3.34; P=0.31)
610121422
or after three days (2.15, 0.48 to 9.60; P=0.32)
1012 of
symptom onset. When studies were stratified by length
of follow-up (≤3 months v >3 months), no difference in
outcome was observed between the shorter follow-up
period (0.93, 0.63 to 1.36; P=0.70)
61014and longer fol-
low-up period (1.50, 0.83 to 2.69; P=0.18).
6910121422
Type of antiviral had no effect on the overall results
(data not shown). The F test for interaction was not sig-
nificant for any subgroup.
DISCUSSION
Principal findings
Our meta-analysis of data from six randomised con-
trolled trials shows that a high proportion of patients
with Bell’s palsy achieve at least partial facial recovery
when given steroids or steroids and antivirals (89.7%
overall using per protocol data). Our pooled odds
ratio for facial muscle recovery showed that antivirals
provided no added benefit over steroids alone (odds
ratio 1.50, 95% confidence interval 0.83 to 2.69;
P=0.18). The two highest quality studies,
614 which
weredoubleblind,hadthegreatesteffectonthepooled
odds ratio. Subgroup analysis of patients treated within
three days of symptom onset showed similar findings,
Table 1 |Study demographics and therapeutic treatments prescribed in the six studies included in the meta-analysis
Year
published Country Study type
Number of
patients on
steroids only
at follow-up
Number of
patients on
steroids plus
antivirals at
follow-up Type of steroid Steroid dose
Type of
antiviral Antiviral dose
Adour et al
22 1996 UnitedStates RCT (double
blind)
46 53 Prednisolone oral 1 mg/kg/day for
5 days followed by
taper to 10 mg/kg/
day over 5 days
Aciclovir 2000mg/dayfor
10 days
Hato et al
12 2007 Japan RCT(singleblind) 107 114 Prednisolone oral 60 mg/day for
5 days, 30 mg/day
for 3 days, 10 mg/
day for 2 days
Valaciclovir 1000mg/dayfor
5 days
Sullivan et al
6 2007 United
Kingdom
RCT (double
blind)
127 124 Prednisolone oral 50 mg/day for
10 days
Aciclovir 2000mg/dayfor
10 days
Engstrom et al
14 2008 Sweden RCT (double
blind)
180 186 Prednisolone oral 60 mg/day for
5 days, 50 mg/day
for1day,40mg/day
for1day,30mg/day
for1day,20mg/day
for1day,10mg/day
for 1 day
Valaciclovir 3000mg/dayfor
7 days
Minnerop et al
9 2008 Germany RCT(notblinded) 67 50 Prednisone oral 1 mg/kg/day for
4 days, taper over
8d a y s
Famciclovir 250 mg/day for
7 days
Yeo et al
10 2008 South Korea RCT (double
blind)
47 44 Prednisolone oral 1 mg/kg/day for
4d a y s ,6 0m g / k g /
day for 2 days,
40 mg/kg/day for
2d a y s ,2 0m g / k g /
day for 2 days
Aciclovir 2400mg/dayfor
5 days
RCT, randomised controlled trial.
  Engstrom et al 2008
14
  Sullivan et al 2007
6
  Adour et al 1996
22
  Hato et al 2007
12
  Yeo et al 2008
10
  Minnerop et al 20089
Pooled effect
0.93 (0.49 to 1.77)
0.52 (0.17 to 1.61)
3.85 (1.13 to 13.10)
3.15 (0.97 to 10.22)
2.39 (0.58 to 9.90)
1.39 (0.53 to 3.62)
1.50 (0.83 to 2.69)
25.41
15.62
14.09
14.78
11.61
18.50
100.00
0.1 1 10 100
Study
Favours
steroids
Favours steroids
plus antivirals
Odds ratio
(95% CI)
Odds ratio
(95% CI)
Weight
(%)
160/180
122/127
35/46
96/107
40/47
53/67
506/574
Steroids
164/186
115/124
49/53
110/114
41/44
42/50
521/571
Steroids
plus antivirals
No with recovery/
No of patients
Fig 2 | Forest plot of the six included studies ordered according to Jadad score (highest quality
to lowest) showing the odds ratio estimates and their 95% confidence intervals. The pooled
estimate is based on a random effects model
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wise, subgroup analysis of length of follow-up and
typeofantiviral showed nobenefit ofantiviralsinaddi-
tion to steroids.
There are, however, more subtle differences
between the included studiesthat need to be explored.
Firstly,theseverityoffacialmuscleparalysisatpresen-
tation differed between two of the more recent
studies.
612 The mean House-Brackmann grade for
patients in the Sullivan et al study,
6 which showed no
benefitofaddingaciclovirtosteroids,was3.6,whereas
the mean score was 4.3 in the Hato et al study,
29 which
reported a significant benefit of adding valaciclovir. In
subgroup analyses, Hato et al showed that the benefit
ofvalaciclovirwasgreaterinpatientswithseverefacial
paralysis at presentation than in those with moderate
paralysis.
12 Furthermore, Minnerop et al performed a
subgroup analysis of patients who presented with
severe facial muscle paralysis (House-Brackmann
grade of 5 or 6) and found significantly better facial
muscle recovery in patients who received famciclovir
plus steroids than in those on steroids alone (72% v
47%, respectively, achieved normal function).
9 How-
ever, only 18 and 17 patients respectively were
included in this analysis. These data suggest that anti-
viral therapy may benefit in particular those patients
with more severe facial paralysis at presentation. On
the other hand, one of the most recently published
trials, by Engstrom et al,
14 is in opposition to this
argument. Patients in this trial had a median House-
Brackmann grade of 4 at presentation, which is very
similar to the level of palsy observed by Hato et al,
12
and the authors convincingly showed no benefit of
adding valaciclovir to steroids alone.
Secondly, the definition of the primary end point,
facial muscle recovery, was slightly different in the six
studies. The two highest quality studies used complete
facial recovery (House-Brackmann grade of 1) as their
primary end point,
614 whereas the remainder of the
studiesusedpartialfacialrecovery(House-Brackmann
grade of ≥2). It is unclear how this disparity would
change the final results, but if the increment of benefit
of antivirals was small then using partial facial muscle
recoveryasthe endpointcouldshowmore favourable
results for combination therapy. This issue also intro-
duces the question of the best end point to use for a
disease in which a very high proportion of patients
recover with current standard therapy (steroids
alone). Time to facial muscle recovery may be a more
sensitive end point. This end point was analysed by
Engstrom et al and no differences were observed
between treatment arms.
14 Moreover, three other pro-
spective studies that were not included in our analysis
owing to the fact that they used time to facial muscle
recovery as the outcome measure showed no statisti-
cally significant difference in recovery rates with com-
bination therapy.
152611 These studies were small,
however, and may have been underpowered to show
a significant difference in time to recovery.
Thirdly, investigators studying Bell’s palsy rarely
perform thorough molecular diagnostic testing for
viral aetiologies. Varicella zoster virus, for example,
cancausefacialmuscleparalysisintheabsenceofvesi-
cles (zoster sine herpete) and has been reported to be
associated with 8% to 28% of Bell’s palsy cases.
29 This
virusislesssensitivetoantiviralsthanareotherviruses
associatedwithBell’spalsy,andthedosesusedintreat-
ment trials are generally not high enough to treat a
Varicella zoster virus infection. Thus, if patients with
thistypeofinfectionwereincludedinthetrialsstudied
inthismeta-analysis,asmaybethecasefortheSullivan
etalandEngstrometalstudies,
614thepotentialbenefit
of antiviral therapy may be diluted.
  Engstrom et al 2008
14
  Sullivan et al 20076
  Adour et al 1996
22
  Hato et al 200712
  Yeo et al 2008
10
  Minnerop et al 2008
9
Cumulative effect
0.93 (0.49 to 1.77)
0.81 (0.46 to 1.41)
1.17 (0.44 to 3.10)
1.46 (0.61 to 3.47)
1.56 (0.75 to 3.27)
1.50 (0.83 to 2.69)
1.50 (0.83 to 2.69)
0.83
0.45
0.76
0.39
0.24
0.18
0.18
0.2 1 2 0.5 5
Study
Favours
steroids
Favours steroids
plus antivirals
Cumulative
odds ratio
(random) (95% CI)
Cumulative
odds ratio
(random) (95% CI)
Cumulative
P value
Fig 3 | Cumulative forest plot of the six included studies, ordered according to study quality
(highest quality to lowest)
Table 2 |Timing of treatment, outcome definitions, and quality of the six studies included in the meta-analysis
Timing of treatment Outcome definition Quality
Duration of
symptomsbefore
treatment
Maximum
length
of follow-up
Outcome scales
used in study
Definition of positive outcome
for meta-analysis
Equivalent outcome
on House-Brackmann grade Jadad score
Adour et al
22 ≤3 days 4 months Facial paralysis recovery index Facial paralysis recovery index
score >7
Recovery to grade 3 or higher 4
Hato et al
12 ≤3daysor4-7days 6 months Yanagihara score Recovery to 36 points or higher Recovery tograde1 orhigh grade2 3
Sullivan et al
6 ≤72 hours 9 months House-Brackmann grade Recovery to grade 1 Recovery to grade 1 5
Engstrom et al
14 ≤72 hours 12 months Sunnybrook system and House-
Brackmann grade
Complete recovery: Sunnybrook
score 100 or House-Brackmann
grade 1
Recovery to grade 1 5
Minnerop et al
9 <5 days >12 months House-Brackmann grade Recovery to grade 2 Recovery to grade 2 or higher 1
Yeo et al
10 ≤3 days or >3 days 6 months House-Brackmann grade Recovery to grade 2 or higher Recovery to grade 2 or higher 3
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between studies, and the newer agents (valaciclovir
and famciclovir) have greater oral bioavailability. We
observednodifferenceinresultswhenthestudieswere
grouped on the basis of antiviral used.
Strengths and weaknesses of study
A key strength of our meta-analysis is the inclusion of
high quality randomised controlled trials. Non-
randomised trials have been published on the topic of
antivirals in Bell’s palsy
131617; however, one should be
guardedinmakingfinalconclusionsfromthesestudies
giventhe limitationsof the studydesign.Despite other
meta-analyses being performed on the treatment of
Bell’s palsy,
830 our meta-analysis is the first to define
whether the addition of antivirals provides any benefit
overtreatmentwithsteroidsalone.Wepurposelyused
a random effects model owing to our concerns about
study heterogeneity and performed several subgroup
analyses in an attempt to characterise the potential
causes of heterogeneity. Furthermore, we accounted
for publication bias.
Our meta-analysis has some limitations. The Adour
et al study did not report intention to treat analyses
22;
therefore, we used the number of patients at final fol-
low-up as our denominator, as these data were avail-
able for all studies. However, even when the Adour et
al study was removed from the analysis of intention to
treat data, the confidence interval of our pooled odds
ratio still crossed 1 (odds ratio 1.20, 95% confidence
interval 0.93 to 1.56; P=0.163). In addition, when the
three unaccounted lost to follow-up patients from the
Adour et al study were added to either arm, our pri-
mary finding did not notably change. Our subgroup
analyses are limited by the small number of included
studies and thus may lack statistical power. However,
thiswasnotthecaseinoursubgroupanalysisofstudies
thatincludedpatientswhopresentedwithinthreedays
of symptom onset. Finally, three prospective rando-
mised studies were not included in this meta-analysis
as they analysed time to recovery,
111526 and the num-
berofpatientsineacharmwasnotreportedinonesuch
study.
15 In addition, we were unable to obtain the
necessary raw data from the investigators leading
each of these studies. However, none of these three
studies showed a significant benefit of combination
therapy over steroids alone. In fact, in the largest of
these,themeantimetorecoverywasshorterinpatients
on steroids alone (70.7 days) compared with those on
combination therapy (76.4 days), although this differ-
ence was not significant (P=0.977).
11
Conclusions and future research
In patients with Bell’s palsy, adding antivirals to ster-
oids does not provide an added benefit in achieving at
leastpartialfacialmusclerecoverycomparedwithster-
oids alone; therefore, this meta-analysis does not sup-
port the routine addition of antivirals to steroids in
Bell’spalsy.Thebenefitofantiviraltherapycombined
with steroids for patients with severe facial muscle
paralysis at presentation who do not have Varicella
zoster virus reactivation is, however, an ongoing ques-
tion. Future prospective double blind studies that use
modern diagnostics, such as polymerase chain reac-
tion, for the detection of Herpes virus reactivation are
needed to resolve this issue. In addition, such trials
should study newer antivirals, such as valaciclovir or
famciclovir, on the basis of their improved bioavail-
ability over aciclovir.
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Fig 4 | Forest plot of a one study removed analysis showing the odds ratio estimate and 95%
confidence interval if the study specified in the “Study removed” column is not included
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based on the six included studies (solid diamond) and
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shown
WHAT IS ALREADY KNOWN ON THIS TOPIC
Bell’spalsyisthemostcommoncauseoffacialmuscleparalysis,andtreatmentwithsteroids
has been shown to significantly improve recovery compared with placebo
Conflictingresults exist on the benefit of antivirals inaddition to steroids for the treatment of
Bell’sp a l s y
WHAT THIS STUDY ADDS
Our meta-analysis suggests that treatment with antivirals plus steroids does not provide an
added benefit in achieving at least partial facial muscle recovery in patients with Bell’sp a l s y
compared with steroids alone
Future studies should determine the role of adding newer antivirals to steroids in patients
with severe facial muscle paralysis at presentation
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